SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Teva Pharmaceuticals
TEVA 32.68+0.1%11:44 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: yosi s who wrote (177)3/27/1998 12:43:00 PM
From: Harold Engstrom  Read Replies (1) of 340
 
Teva's study is PR and not adequate for labelling changes. Teva couldn't show positive data under rigorous scientific controls so it went and bought a study that would create a marketing splash. If Copaxone can be demonstrated to show effectiveness under rigorous clinicals, then patients should consider it as a second choice to Avonex, Betaseron or Rebif. In my opinion, Teva's management is coming under some serious heat for Copaxone's flop and this is their way of meeting that pressure.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News